Thomas Werfel1, Nicolaus Schwerk2, Gesine Hansen2, Alexander Kapp1. 1. Department of Dermatology and Allergology, Hannover Skin Cancer Center, Hannover Medical School. 2. Clinic for Paediatric Pneumology and Neonatology, Hannover Medical School.
Abstract
BACKGROUND: Atopic dermatitis is the most common skin disease in children, with a prevalence of 10% to 15%, and is common in adults as well. Close coordination between primary care physicians and specialists is essential for the adequate treatment of chronically and severely affected patients. METHOD: This article is a review of pertinent publications that were retrieved by a selective search in Pubmed, with additional consideration of the guidelines of the Association of Medical Scientific Societies in Germany (AWMF) and the European Dermatology Forum. RESULTS: Trigger factors such as skin irritants, allergens, microbial pathogens, and psychological factors can affect the condition of the skin differently in individual patients and should be individually assessed. The use of skin moisturising creams or emollients along with avoidance of specific and unspecific irritants is of great importance, as these patients have an impaired cutaneous barrier. Topical anti-inflammatory treatment with glucocorticoids or calcineurin inhibitors is a central part of the management of atopic dermatitis; in exceptional cases, severely affected patients are treated with systemic anti-inflammatory drugs. Interdisciplinary patient education has been found to be an effective tool in the complex management of this disease. Chronically and severely affected patients present special challenges for diagnosis and treatment. CONCLUSION: Recent advances in the understanding of the molecular basis of cutaneous barrier disorders and of congenital and acquired immune disorders have led to new approaches to the treatment of atopic dermatitis.
BACKGROUND:Atopic dermatitis is the most common skin disease in children, with a prevalence of 10% to 15%, and is common in adults as well. Close coordination between primary care physicians and specialists is essential for the adequate treatment of chronically and severely affected patients. METHOD: This article is a review of pertinent publications that were retrieved by a selective search in Pubmed, with additional consideration of the guidelines of the Association of Medical Scientific Societies in Germany (AWMF) and the European Dermatology Forum. RESULTS: Trigger factors such as skin irritants, allergens, microbial pathogens, and psychological factors can affect the condition of the skin differently in individual patients and should be individually assessed. The use of skin moisturising creams or emollients along with avoidance of specific and unspecific irritants is of great importance, as these patients have an impaired cutaneous barrier. Topical anti-inflammatory treatment with glucocorticoids or calcineurin inhibitors is a central part of the management of atopic dermatitis; in exceptional cases, severely affected patients are treated with systemic anti-inflammatory drugs. Interdisciplinary patient education has been found to be an effective tool in the complex management of this disease. Chronically and severely affected patients present special challenges for diagnosis and treatment. CONCLUSION: Recent advances in the understanding of the molecular basis of cutaneous barrier disorders and of congenital and acquired immune disorders have led to new approaches to the treatment of atopic dermatitis.
Authors: Ulrich Mrowietz; C Eberhard Klein; Kristian Reich; Thomas Rosenbach; Thomas Ruzicka; Michael Sebastian; Thomas Werfel Journal: J Dtsch Dermatol Ges Date: 2009-03-19 Impact factor: 5.584
Authors: Mandy E Schram; Rinke J Borgonjen; Cathelijne M J M Bik; Jan G van der Schroeff; Jannes J E van Everdingen; Phyllis I Spuls Journal: Arch Dermatol Date: 2011-04
Authors: H Aubert-Wastiaux; L Moret; A Le Rhun; A M Fontenoy; J M Nguyen; C Leux; L Misery; P Young; M Chastaing; N Danou; P Lombrail; F Boralevi; J P Lacour; J Mazereeuw-Hautier; J-F Stalder; S Barbarot Journal: Br J Dermatol Date: 2011-09-15 Impact factor: 9.302
Authors: Cristina Woellner; E Michael Gertz; Alejandro A Schäffer; Macarena Lagos; Mario Perro; Erik-Oliver Glocker; Maria C Pietrogrande; Fausto Cossu; José L Franco; Nuria Matamoros; Barbara Pietrucha; Edyta Heropolitańska-Pliszka; Mehdi Yeganeh; Mostafa Moin; Teresa Español; Stephan Ehl; Andrew R Gennery; Mario Abinun; Anna Breborowicz; Tim Niehues; Sara Sebnem Kilic; Anne Junker; Stuart E Turvey; Alessandro Plebani; Berta Sánchez; Ben-Zion Garty; Claudio Pignata; Caterina Cancrini; Jiri Litzman; Ozden Sanal; Ulrich Baumann; Rosa Bacchetta; Amy P Hsu; Joie N Davis; Lennart Hammarström; E Graham Davies; Efrem Eren; Peter D Arkwright; Jukka S Moilanen; Dorothee Viemann; Sujoy Khan; László Maródi; Andrew J Cant; Alexandra F Freeman; Jennifer M Puck; Steven M Holland; Bodo Grimbacher Journal: J Allergy Clin Immunol Date: 2010-02 Impact factor: 10.793
Authors: Thomas Werfel; Annice Heratizadeh; Werner Aberer; Frank Ahrens; Matthias Augustin; Tilo Biedermann; Thomas Diepgen; Regina Fölster-Holst; Uwe Gieler; Julia Kahle; Alexander Kapp; Alexander Nast; Katja Nemat; Hagen Ott; Bernhard Przybilla; Martin Roecken; Martin Schlaeger; Peter Schmid-Grendelmeier; Jochen Schmitt; Thomas Schwennesen; Doris Staab; Margitta Worm Journal: Allergo J Int Date: 2016-05-02
Authors: K Tengvall; K Bergvall; M Olsson; B Ardesjö-Lundgren; F H G Farias; M Kierczak; Å Hedhammar; K Lindblad-Toh; G Andersson Journal: Immunogenetics Date: 2020-06-18 Impact factor: 2.846
Authors: Linh Ha-Wissel; Handan Yasak; Robert Huber; Detlef Zillikens; Ralf J Ludwig; Diamant Thaçi; Jennifer E Hundt Journal: Front Med (Lausanne) Date: 2022-09-27
Authors: M R López-Álvarez; W Jiang; D C Jones; J Jayaraman; C Johnson; W O Cookson; M F Moffatt; J Trowsdale; J A Traherne Journal: Immunogenetics Date: 2016-06-22 Impact factor: 2.846